OncoMatch/Clinical Trials/NCT05937906
Clinical Trial Evaluating the Safety and Efficacy of Chemoimmunotherapy Plus Short Course of Mek Inhibitor in First Line of Treatment of Metastatic Non Squamous Non Small Cell Lung Adenocarcinoma With PDL1 < 50 %.
Is NCT05937906 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments for non-small cell lung cancer.
Treatment: Phase I - Mirdametinib - Level 1 · Phase II - Mirdametinib · Phase I - Mirdametinib - Level 2 · Phase I - Mirdametinib - Level 3 · Phase I - Mirdametinib - Level 4 — Monocentric study composed by 2 steps : 1. First step is a phase I with the aim of establish the recommended dose of mirdametinib administration (2 or 4 mg twice a day for 7 or 14 days per cycle for the 4 first of carboplatin/pemetrexed/pembrolizumab treatment) 2. Second step is a non comparative randomized (2:1) phase II trial testing the recommended dose of mirdametinib administration. The aim is the efficacy and safety of short course of mirdametinib treatment for the 4 first cycles of the carboplatin/pemetrexed/pembrolizumab treatment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR targetable mutation
Presence of EGFR, ROS or ALK targetable mutations [excluded]
Required: ALK targetable mutation
Presence of EGFR, ROS or ALK targetable mutations [excluded]
Required: ROS1 targetable mutation
Presence of EGFR, ROS or ALK targetable mutations [excluded]
Required: PD-L1 (CD274) expression < 50% (TPS) (< 50%)
PD-L1<50% using TPS scoring
Disease stage
Metastatic disease required
Patients must be diagnosed with a metastatic or locally advanced non squamous non-small cell lung cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic therapy
Exception: Previous adjuvant therapy is allowed if > 12 months from the last injection
Absence of previous treatment for or locally advanced or metastatic non-small cell lung cancer. Previous adjuvant therapy is allowed if > 12 months from the last injection
Lab requirements
Blood counts
Adequate normal organ and marrow function as defined below
Kidney function
Adequate normal organ and marrow function as defined below
Liver function
Adequate normal organ and marrow function as defined below
Cardiac function
QTc < 450 msec on baseline ECG (Fridericia correction cQTcF); LVEF ≥ 50%
Adequate normal organ and marrow function as defined below: Adequate cardiac function: (QTc < 450 msec on baseline ECG, using the Fridericia correction cQTcF formula) or other clinically significant ventricular or atrial arrhythmia. Left ventricular ejection fraction (LVEF) ≥ 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify